SHORTAGES of multiple brands of methylphenidate hydrochloride products, used for treatment of ADHD, are expected to be low in stock for the remainder of 2025, according to the Therapeutic Goods Administration (TGA).

The government body has convened a Methylphenidate Medicine Shortage Action Group (MSAG) which will consult with health professional groups for input into helping to manage the shortage.

One such body, The Australasian ADHD Professionals Association, has developed guidelines to help clinicians manage the shortage.

These feature information, also available on the Medicine Shortage Reports Database, to guide staff through switching from methylphenidate to either lisdexamfetamine or dexamfetamine IR – CLICK HERE for more information.

The post Meds not in stock appeared first on Pharmacy Daily.